Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 1.00 |
| ▸ | ESRRG | P62508 | 8/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ESRRB | O95718 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PLD2 | O14939 | 1/20 | 1.00 |
| ▸ | PLD1 | Q13393 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afimoxifene SCHEMBL9189 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| SCHEMBL15668666 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL2132301 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL640496 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL11899365 | 0.99 | ESR1 (0.97) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL9121934 | 0.97 | ESR1 (0.95) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL7649806 | 0.95 | ESR1 (0.91) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL7649812 | 0.95 | ESR1 (0.91) | ESR1ESRRGESR2MAPTESRRB | |
| SCHEMBL9857240 | 0.95 | ESR1 (0.90) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL1056785 | 0.95 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12270803-B2 | Quantitation of tamoxifen and metabolites thereof by mass spectrometry | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2025-04-08 | — | — | US | claimed |
| US-20240060950-A1 | QUANTITATION OF TAMOXIFEN AND METABOLITES THEREOF BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2024-02-22 | — | — | US | claimed |
| EP-3558924-B1 | METHODS OF USING 4-HYDROXY-2,2,6,6-TETRAMETHYLPIPERIDINOXYL (4-HT) AS POLYMERIZATION INHIBITOR IN A WASH SETTLER FOR PREPARING METHYL METHACRYLATE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3810184-A2 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | University of Rochester (US) | 2021-04-28 | — | — | EP | claimed |
| CN-112654366-A | Methods of treating or inhibiting the onset of huntington's disease | 罗切斯特大学 | 2021-04-13 | — | — | CN | claimed |
| US-20260118337-A1 | QUANTITATION OF TAMOXIFEN AND METABOLITES THEREOF BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVEST LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | Convergent Health Sciences LLC: (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4713455-A1 | GENOME EDITING COMPOSITIONS TARGETING THE B2M GENE AND METHODS OF USE | Prime Medicine, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12565666-B2 | Methods and compositions for modulating a genome | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| CN-121586577-A | Genome editing compositions and methods of use | 先导药物有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20260050822-A1 | DETECTING SUSPICIOUS ACTIVITY USING BAYESIAN NETWORKS | ORACLE INTERNATIONAL CORPORATION (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260021180-A1 | IMPROVING ADOPTIVE CELL TRANSFER THERAPY (ACT) TREATMENT | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-01-22 | — | — | US | disclosed |
| US-6156723-A | Compositions comprising inhibitors of estrogen response | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-05 | — | — | US | disclosed |
| WO-1998012327-A2 | COMPOSITIONS AND METHODS COMPRISING BARD1 AND OTHER BRCA1 BINDING PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-03-26 | — | — | WO | disclosed |
| US-5723291-A | CELLS WITH PROTEIN AND DETECTION OF GENE EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0819169-A1 | METHODS FOR SCREENING COMPOUNDS FOR ESTROGENIC ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-01-21 | — | — | EP | disclosed |
| EP-0724648-A4 | METHODS FOR SCREENING ANTIESTROGEN COMPOUNDS | UNIV CALIFORNIA (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1996030505-A1 | METHODS FOR SCREENING COMPOUNDS FOR ESTROGENIC ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0724648-A1 | METHODS FOR SCREENING ANTIESTROGEN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995006754-A1 | METHODS FOR SCREENING ANTIESTROGEN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260118337-A1 | QUANTITATION OF TAMOXIFEN AND METABOLITES THEREOF BY MASS SPECTROMETRY | ESR1, ESR2, PTMS | ESR1 1/4885ESRRG 14/4885ESR2 2/4885 |
| US-12611417-B1 | Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines | PLCB1, PHKG1, PLCB3 | ESR1 3994/4885ESRRG 4352/4885ESR2 4140/4885 |
| US-20260021180-A1 | IMPROVING ADOPTIVE CELL TRANSFER THERAPY (ACT) TREATMENT | SLC2A9, PBK, HK2 | ESR1 4321/4885ESRRG 3220/4885ESR2 4410/4885 |
| US-20260050822-A1 | DETECTING SUSPICIOUS ACTIVITY USING BAYESIAN NETWORKS | BCR, BTK, STAT4 | ESR1 108/4885ESRRG 508/4885ESR2 290/4885 |
| US-12565666-B2 | Methods and compositions for modulating a genome | RPRD2, ERN2, TPR | ESR1 238/4885ESRRG 350/4885ESR2 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.